Bristol Meyers Squibb Case Analysis

1565 Words 7 Pages
Bristol Meyers Squibb is a pharmaceutical company, with a very rich tradition. This analysis will begin with a few historical highlights. Edward Squibb was a doctor in the Navy, who was unimpressed by the medicine that the Navy was using during the Mexican War, he was so dissatisfied that he threw all of the unfit medicine overboard. On 1858, when he returned, he went on to start his own company in Brooklyn, New York, with the goal of having pure medicine for the people. Squibb’s medicine was such a success it was used as the main source for the Union in the Civil War.
William Bristol and his good friend John Meyers paid $5,000 for Clinton Pharmaceutical Company, which was on its way to failing. Meanwhile Squibb retired and left his business to his two sons, who would late rename the company E.R. Squibb & Sons. Both, began to make moves within industry, creating new products and implementing effective marketing plans. In 1924 Bristol Meyers became a publicly traded company on the New York Stock Exchange. Bristol Meyers began
…show more content…
Currently BMY is lowest in price that it has been in years. Nevertheless, BMY is a strong company with good financials, strong liquidity, and good reputation. Furthermore, it may not happen over nigh but the company will most likely have a comeback. As previously stated many of the competitors also bring good value, whether it is in capital gains yield or dividend yield. However in this specific case, as an investor BMY would be the best value because it has a constant dividend that has continued to increase year after year. Capital gains of a stock can change, but dividends are real cash that is received, and this stock could be used as a constant income stream. In conclusion, and to the best of my knowledge I believe that BMY is the best long term value out of the four pharmaceutical companies mentioned

Related Documents